• Clini'/> Selection of Protein Kinase Inhibitors Based on Tumor Tissue Kinase Activity Profiles in Patients with Refractory Solid Malignancies: An Interventional Molecular Profiling Study
    首页> 美国卫生研究院文献>The Oncologist >Selection of Protein Kinase Inhibitors Based on Tumor Tissue Kinase Activity Profiles in Patients with Refractory Solid Malignancies: An Interventional Molecular Profiling Study
    【2h】

    Selection of Protein Kinase Inhibitors Based on Tumor Tissue Kinase Activity Profiles in Patients with Refractory Solid Malignancies: An Interventional Molecular Profiling Study

    机译:基于难治性实体恶性肿瘤患者肿瘤组织激酶活性谱的蛋白激酶抑制剂选择:介入分子谱研究

    代理获取
    本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

    摘要

    Lessons Learned. class="unordered" style="list-style-type:disc" id="onco12594-list-0001">
  • Clinically applicable tools are needed for treatment selection and repurposing of available protein kinase inhibitors (PKIs) in patients with advanced solid tumors refractory to standard treatment.
  • Using a tyrosine kinase peptide substrate microarray, observed inhibitory activity in vitro could not sufficiently predict clinical benefit of treatment with the selected PKI.
    机译:得到教训。 class =“ unordered” style =“ list-style-type:disc” id =“ onco12594-list-0001”> <!-list-behavior = unordered prefix-word = mark-type = disc max-label- size = 0->
  • 需要临床适用的工具来选择治疗以及重新利用标准治疗难以治疗的晚期实体瘤患者中可用的蛋白激酶抑制剂(PKI)。
  • 使用酪氨酸激酶肽底物微阵列,观察到的体外抑制活性不能充分预测所选PKI的临床疗效。

    著录项

    相似文献

    • 外文文献
    • 中文文献
    • 专利
    代理获取

    客服邮箱:kefu@zhangqiaokeyan.com

    京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
    • 客服微信

    • 服务号